Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
αCD276 CAR-DNT cells
- Development stage
- Preclinical
- Lead developer
- University of Calgary
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumoral
01
Overview
αCD276 CAR-DNT cells are an experimental allogeneic cell therapy consisting of double-negative T (DNT) cells (CD3+CD4-CD8-) engineered with a second-generation chimeric antigen receptor (CAR) containing a 4-1BB costimulatory domain targeting CD276 (B7-H3). Developed by researchers at the University of Calgary, these cells are designed to treat glioblastoma (GBM) by addressing spatial heterogeneity. DNT cells are utilized for their innate anti-tumor cytotoxicity and their suitability for allogeneic use without inducing graft-versus-host disease (GvHD). In preclinical models, these cells have shown the ability to target both the tumor core and the infiltrative edge, potentially overcoming the limitations of conventional CAR-T therapies in heterogeneous brain tumors.
- Other names
- anti-CD276 CAR-DNT cellsanti-CD-276 CAR-DNT cellsanti-CD 276 CAR-DNT cellsB7-H3 CAR-DNT cellsB-7-H3 CAR-DNT cellsB 7-H3 CAR-DNT cellsCD276-targeted CAR-DNT cellsCD-276-targeted CAR-DNT cellsCD 276-targeted CAR-DNT cells
02
Targets
B7-H3
Beyond the preview
Go deeper on αCD276 CAR-DNT cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on αCD276 CAR-DNT cells.